San Diego, CA, United States of America

Isaac Marks

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Isaac Marks in Dystrophin Research

Introduction

Isaac Marks is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the treatment of muscle dystrophies. With a total of 2 patents, his work focuses on innovative solutions for complex medical challenges.

Latest Patents

Isaac Marks' latest patents include the development of anti-transferrin receptor antibody-PMO conjugates for inducing Duchenne muscular dystrophy (DMD) exon 44 skipping. These patents disclose antibody oligonucleotide conjugates and pharmaceutical compositions that induce an alteration in incorrectly spliced dystrophin mRNA transcripts to promote exon 44 skipping. The methods described in these patents aim to treat muscle dystrophy, including DMD, by administering these conjugates or pharmaceutical compositions.

Career Highlights

Throughout his career, Isaac has worked with notable organizations such as Avidity Biosciences, Inc. and Purdue Research Foundation. His experience in these companies has allowed him to advance his research and contribute to the development of innovative therapies.

Collaborations

Isaac has collaborated with talented individuals in his field, including Beatrice Diana Darimont and Usue Etxaniz Irigoien. These partnerships have further enriched his research and innovation efforts.

Conclusion

Isaac Marks continues to be a pivotal figure in the realm of biotechnology, focusing on groundbreaking solutions for muscle dystrophies. His patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…